Michael Faulkner, MD
Interventional Cardiology · Paducah, KYNPI 1336342427
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,887 of the $12,753 with a category attached, or 77.5%. 31 manufacturers reported payments, led by Medtronic at 24.8% of the total. Reporting peaked in 2019 at $3,837 and has fallen 79.5% since, to $785 in 2025.
Across 451 payments — averaging $28.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Abbott$2K
- Edwards Lifesciences$1K
- Novartis$1K
- Boston Scientific$606
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$597
- plus $4K from 25 others
What the payments were for
- Travel & lodging$2,85222%
- Food & beverage$9,88778%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 33 | $3,162 |
| Abbott | 30 | $1,939 |
| Edwards Lifesciences | 41 | $1,398 |
| Novartis | 69 | $1,055 |
| Boston Scientific | 23 | $606 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 45 | $597 |
| Inari Medical, Inc. | 9 | $548 |
| Pfizer | 38 | $511 |
| AstraZeneca | 6 | $396 |
| Johnson & Johnson | 33 | $395 |
| Abiomed | 6 | $363 |
| Boehringer Ingelheim | 24 | $348 |
| E.r. Squibb & Sons, L.L.C. | 25 | $342 |
| Amgen | 23 | $322 |
| Sanofi-aventis U.S. LLC | 11 | $129 |
| Lantheus Medical Imaging, Inc. | 6 | $108 |
| Astellas Pharma US Inc | 5 | $91 |
| Shockwave Medical, Inc | 4 | $79 |
| Philips North America LLC | 4 | $76 |
| Irhythm Technologies, Inc. | 3 | $50 |
| Braemar Manufacturing, LLC | 1 | $39 |
| Otsuka America Pharmaceutical, Inc. | 1 | $31 |
| Merck | 2 | $31 |
| Elutia, Inc. | 2 | $26 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Biosense Webster, Inc. | 1 | $17 |
| Inspire Medical Systems, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Portola Pharmaceuticals, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$1,588
- MitraClip$1,160
- Micra$741
- FLOWTRIEVER CATHETER, S$436
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$236
- CT THROMBECTOMY SYSTEM KIT$200
- Mitra Clip system$155
- Impella$141
- PASCAL$132
- WATCHMAN Access System$119
- Watchman$105
How this compares
$12,753 in reported general payments places this provider in the 60th percentile of 129 interventional cardiology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 403 | $360,462 |
| Repatha SureclickEvolocumab | 124 | $96,941 |
| XareltoRivaroxaban | 75 | $85,783 |
| EntrestoSacubitril/Valsartan | 51 | $73,545 |
| BrilintaTicagrelor | 62 | $50,612 |
| MultaqDronedarone Hcl | 20 | $19,467 |
| Praluent PenAlirocumab | 32 | $18,677 |
| JardianceEmpagliflozin | 22 | $17,154 |
| FarxigaDapagliflozin Propanediol | 17 | $16,609 |
| Ranolazine ErRanolazine | 139 | $15,328 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 15 | $5,925 |
| Atorvastatin Calcium | 397 | $3,632 |
| Metoprolol Succinate | 241 | $2,653 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 287 | $2,642 |
| ClopidogrelClopidogrel Bisulfate | 164 | $1,517 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $511 | $360,462403 claims |
| Johnson & JohnsonXarelto | $395 | $85,78375 claims |
| NovartisEntresto | $1,055 | $73,54551 claims |
| AstraZenecaBrilinta, Farxiga | $396 | $67,22279 claims |
| Sanofi-aventis U.S. LLCMultaq | $129 | $19,46720 claims |
| Boehringer IngelheimJardiance | $348 | $17,15422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 129 interventional cardiology providers in Kentucky.
Other interventional cardiology in Paducah
- James FordPaducah$67K
- Shankho GanguliPaducah$56K
- Martin RainsPaducah$45K
- Timothy McDermottPaducah$17K
- Amit SrivastavaEdgewood$642K
- Avichai EresLexington$616K
- Steve LinLexington$362K
- Daniel StewartLouisville$290K
- Robert SawyerLexington$249K
- Ganesh Keshav ThirunavukkarasuLexington$220K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.